trutino-lab

Session Type: E-Poster Session
Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions
Presenter: Dr. Emma Langley
Permanent Abstract Number: 1745

Categories: Biotech, News, Technology

by Emma Langley

Share

STAY IN THE LOOP

Subscribe to our free newsletter.

Don’t have an account yet? Get started with a 12-day free trial

Related Posts

View all
  • Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company. Led by Phillip Kim, Ph.D., MBA, Founder and […]

    Continue reading
  • Abstract Background An emerging class of new protease-activatable prodrugs designed to enhance on-target activity and reduce off-target toxicity are being actively developed. Cytokines […]

    Continue reading
  • Abstract Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal […]

    Continue reading
  • Boehringer Ingelheim has struck a deal with Trutino Biosciences to develop three cytokine therapies. The deal tasks Trutino with applying a platform designed […]

    Continue reading